Translational Implications for Radiosensitizing Strategies in Rhabdomyosarcoma.
Silvia PomellaAntonella PorrazzoMatteo CassandriSimona CameroSilvia CodenottiLuisa MilazzoFrancesca VulcanoGiovanni BarillariGiovanni CenciCinzia MarcheseAlessandro FanzaniFrancesca MegiorniRossella RotaFrancesco MaramponPublished in: International journal of molecular sciences (2022)
Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma of childhood and adolescence that includes FP-RMS, harboring the fusion oncoprotein PAX3/7-FOXO1 and FN-RMS, often mutant in the RAS pathway. Risk stratifications of RMS patients determine different prognostic groups and related therapeutic treatment. Current multimodal therapeutic strategies involve surgery, chemotherapy (CHT) and radiotherapy (RT), but despite the deeper knowledge of response mechanisms underpinning CHT treatment and the technological improvements that characterize RT, local failures and recurrence frequently occur. This review sums up the RMS classification and the management of RMS patients, with special attention to RT treatment and possible radiosensitizing strategies for RMS tumors. Indeed, RMS radioresistance is a clinical problem and further studies aimed at dissecting radioresistant molecular mechanisms are needed to identify specific targets to hit, thus improving RT-induced cytotoxicity.
Keyphrases
- end stage renal disease
- healthcare
- machine learning
- chronic kidney disease
- radiation therapy
- early stage
- locally advanced
- depressive symptoms
- transcription factor
- working memory
- coronary artery disease
- cell proliferation
- prognostic factors
- acute coronary syndrome
- pain management
- diabetic rats
- deep learning
- dna repair
- percutaneous coronary intervention
- dna damage response
- patient reported outcomes
- patient reported